WASHINGTON (AP) - A panel of U.S. respiratory experts has voted in favor of approving an experimental inhaler drug from GlaxoSmithKline and Theravence for treating chronic lung disease.
A majority of Food and Drug Administration panelists voted that the Breo Ellipta inhaler is safe and effective for long-term use and to control flare ups in patients with chronic obstructive pulmonary disorder.
The FDA is not required to follow the group's recommendation, though it often does.
The ailment, often called smoker's cough, can cause a number of breathing problems, including chronic bronchitis and emphysema.
Breo is a combination of two respiratory drugs that help to open lung airways and reduce swelling. The combination drug is designed to be used with the Ellipta inhaler device.
Copyright 2013 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Republican Governor Scott Walker addressed a controversial campaign letter Thursday while in Green Bay for a groundbreaking.
A local landmark, for good or bad, in Grand Chute could soon be coming down.
We're spreading a little holiday cheer to area military families this year.
An Allouez man who has not been seen in a week could be at risk without his medication, Brown County sheriff’s officials say.
The DNR says six private wells in the Manitowoc County town of Newton are showing signs of contamination.
Time continues to tick away as to whether or not Walmart can continue to have exclusive rights to a piece of property in Green Bay's Broadway District.